An observational study in Neuromyelitis Optica, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by University of Texas Southwestern Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Neuromyelitis Optica with a site in United States — 16 open to participants now, 21 under way, 2 of them phase 3. Neuromyelitis Optica · United States.
Among the 52 studies in Neuromyelitis Optica with a site in United States, this one is the 13th largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2024, is one of 15 observational ones, reaches primary completion later than 12 of the 20 other live ones, and was the 49th registered.
178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.
Browse Neuromyelitis Optica studies →16 of the 52 studies in Neuromyelitis Optica with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 15+ · Women only
Hoffmann-La Roche · Sites in United States, Argentina, China and 6 more countries
Ages 2–11
Anastasia Vishnevetsky, MD, MPH · Sites in United States
Ages 18+
TG Therapeutics, Inc. · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 14 · Phase 3 11 · Phase 4 3
First in 2001; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 200 across 62 observational studies indexed under Neuromyelitis Optica.
Median enrollment 22 across the 37 interventional studies, 112 across the 15 observational. Of the 26 that completed or were terminated, 19 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 52 have an industry lead sponsor. The 10 most frequent:
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
University of Texas Southwestern Medical Center has 3 studies filed under Neuromyelitis Optica — fewer than ten, so there is no comparison to draw.
5 of the studies in Neuromyelitis Optica with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05199688Phase 3Hoffmann-La RocheA Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) | 2027-03-31 |
| NCT06680037TG Therapeutics, Inc.A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | 2026-12-01 |
| NCT05549258AmgenStudy of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder | 2027-04-13 |
| NCT06453694Anastasia Vishnevetsky, MD, MPHEfgartigimod for the Treatment of Acute Optic Neuritis | 2027-06 |
| NCT03011541MD Stem CellsStem Cell Ophthalmology Treatment Study II | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 52 studies in Neuromyelitis Optica with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational study to:
This is a single-center prospective observational study with all participants recruited from The University of Texas Southwestern Medical Center in Dallas, Texas. Enrollment of 35 people with aquaporin-4 IgG antibody positive neuromyelitis optica spectrum disorder is planned with all individuals treated with commercially supplied ravulizumab at the recommendation of the healthcare provider, with use consistent with the approved indication and labeling.
The study is composed of the following:
Open-label treatment with commercially covered ravulizumab: Enrolled subjects will be treated with ravulizumab in a manner consistent with the FDA approved labeling. All prescreening laboratory tests, vaccinations, and clinical surveillance studies will be ordered and managed by the Primary Clinical Team.
Treatment with ravulizumab will continue throughout the course of the study unless one of the following events occur: a. An individual loses commercial coverage for ravulizumab; b. Discontinuation of the medication by the clinical team is recommended due to an adverse reaction, intolerability, or inadequate disease control. The decision regarding treatment will be determined by the Primary Clinical Team and the patient; c. The participant prematurely discontinues treatment for personal reasons
In the event that the medication is discontinued prematurely, participants will continue to be followed throughout the 156 week period with all clinical, radiological, and serological assessments performed.
The study population will consist of male and female adult participants recruited from The Multiple Sclerosis and Neuroimmunology Clinic at The University of Texas Southwestern Medical Center in Dallas, Texas.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
35 people with aquaporin-4 IgG antibody positive neuromyelitis optica spectrum disorder is planned with all individuals treated with commercially supplied ravulizumab at the recommendation of the healthcare provider, with use consistent with the approved indication and labeling. Approximately 50% of the cohort is anticipated to be Black/African American based on existing internal data.
Drug: Ravulizumab
All study participants will receive commercially covered ravulizumab consistent with the indication, dose and frequency contained within the approved label.
Number of participants with clinical relapses before and after treatment with ravulizumab
Compare the number of participants with adjudicated clinical relapses both pre- and post-ravulizumab treatment
Time frame: 52 weeks - 78 weeks in primary phase, 78 weeks in extension phase.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Apr 2029, 57 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2026 → Apr 2029 and completion Jun 2027 → Oct 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas Southwestern Medical Center →